Generic Medicine Info
Indications and Dosage
Adjunct for seizures associated with the Lennox-Gastaut syndrome
Adult: <30 kg: Initially, 200 mg daily in 2 equally divided doses, increased in increments of 200 mg daily every 2 days according to response. Max: 1,000 mg daily (without valproate); 600 mg daily (with valproate); ≥30 kg: Initially, 400 mg daily in 2 equally divided doses, gradually increased by increments of 400 mg daily every 2 days. Max: 30-50 kg: 1,800 mg daily; >50-70 kg: 2,400 mg daily; >70 kg: 3,200 mg daily.
Child: 4-17 years Same as adult dose.
Hepatic Impairment
Severe: Contraindicated.
Familial short QT syndrome. Severe hepatic impairment.
Special Precautions
Avoid abrupt withdrawal. Mild to moderate hepatic impairment. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Shortened QT interval, leucopenia, status epilepticus, ataxia, dizziness, gait disturbance, somnolence, fatigue, suicidal ideation and behaviour.
Blood and lymphatic system disorders: Anaemia.
Ear and labyrinth disorders: Ear infection.
Eye disorders: Nystagmus, diplopia, blurred vision.
Gastrointestinal disorders: Nausea, vomiting, constipation, dyspepsia, upper abdominal pain.
Metabolism and nutrition disorders: Decreased appetite.
Musculoskeletal and connective tissue disorders: Back pain.
Nervous system disorders: Headache, dizziness, vertigo, tremor.
Psychiatric disorders: Aggression (children), psychomotor hyperactivity (children), anxiety.
Respiratory, thoracic and mediastinal disorders: Influenza, nasopharyngitis, rhinitis, sinusitis, bronchitis.
Skin and subcutaneous tissue disorders: Pruritus, rash.
Potentially Fatal: Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome.
Patient Counseling Information
This drug may cause blurred vision, dizziness, and somnolence, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor for signs and symptoms of suicide ideation; rash; frequency and duration of seizures.
Drug Interactions
Increased plasma concentrations with valproate. May decrease the effect of oral contraceptives. May increase plasma levels of phenytoin and phenobarbital. May decrease plasma levels of carbamazepine and lamotrigine.
Food Interaction
Food increases absorption.
Description: Rufinamide modulates the activity of sodium channels through prolongation of their inactive state, thereby limiting the repetitive firing of sodium-dependent action potentials mediating anticonvulsant effects.
Absorption: Slowly and extensively absorbed from the GI tract. Bioavailability: ≥85%; increased with food. Time to peak plasma concentration: 4-6 hours.
Distribution: Evenly distributed between erythrocytes and plasma. Volume of distribution: Approx 50 L. Plasma protein binding: 34%, mainly to albumin.
Metabolism: Extensively metabolised via carboxylesterase-mediated hydrolysis of the carboxylamide group to inactive acid derivative CGP 47292.
Excretion: Via urine (85%, approx 66% as CGP 47292, 2% as unchanged drug). Elimination half-life: Approx 6-10 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Rufinamide, CID=129228, (accessed on Jan. 23, 2020)

Store at 25°C. Protect from moisture.
MIMS Class
ATC Classification
N03AF03 - rufinamide ; Belongs to the class of carboximide derivatives antiepileptic. Used in the management of epilepsy.
Anon. Rufinamide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 07/02/2018.

Banzel Tablet, Film Coated; Banzel Suspension (Eisai Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 08/02/2018.

Buckingham R (ed). Rufinamide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 08/02/2018.

Joint Formulary Committee. Rufinamide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 08/02/2018.

McEvoy GK, Snow EK, Miller J et al (eds). Rufinamide. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 08/02/2018.

Disclaimer: This information is independently developed by MIMS based on Rufinamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in